Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia
Status:
Completed
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
The main objective of this study is to compare microglia activation as measured with proton
Magnetic Resonance Spectroscopy (1H-MRS) between recent-onset schizophrenia patients who are
randomised to CBD and those randomised to placebo.